The economics of lung cancer management in Canada.

摘要: Because lung cancer is a major health care problem in Canada, it imperative to understand how resources are used diagnose and treat this disease. This paper describes method of modelling the direct patient costs for from perspective government as payer universal system. Clinical algorithms were developed describe management non-small cell (NSCLC) small (SCLC) cancer. Patients allocated treatment model based on knowledge their distribution by type stage Canadian cases. A microsimulation Statistics Canada was integrate data cancer, extent disease, clinical management, survival resource utilization. The diagnosis NSCLC ranged $Cdn 17 889 surgery/post-operative radiotherapy Stages I II 6333 supportive patients with Stage IV determining relapse estimated be 1528 terminal costs, made up largely hospitalization charges some palliative radiotherapy, 10 331. Direct initial SCLC 18 691 limited disease 4739 extensive cost 1590 averaged 9966. For all 15 624 cases diagnosed 1988, that total providing follow-up, managing over 5 years 328 million. Despite large estimates effectiveness therapy showed per life year gained approximately 11 000 19 560 SCLC. These assume have access care, uncomplicated practice standard, must viewed an idealized assessment management. model, however, does provide useful framework evaluating new diagnostic procedures, strategies drugs.